findmyKOL
Clinical trialNCT06138587RecruitingPhase 1Interventional

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

SponsorDana-Farber Cancer InstituteEnrollment15Acute Myeloid LeukemiaLeukemiaLeukemia, MyeloidMyelodysplastic SyndromesMyeloproliferative DisordersMyeloproliferative Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. Names of the study therapies involved in this study are: * CIML NK cells intravenous infusion (cellular therapy) * Subcutaneous Interleukin-2 (recombinant, human glycoprotein)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Roman Shapiro, MD
    Not, yet, recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Roman Shapiro, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cytokine Induced Memory-like Natural Killer CellsInterleukin-2
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
24 Jan 2024
Primary completion
28 Feb 2027
Completion
30 Nov 2027
Last update posted
17 Jun 2026
Registered enrollment
15
Registry id
NCT06138587
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.